TRxADE HEALTH, Inc. (NASDAQ:MEDS – Get Rating) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 715,400 shares, an increase of 464.2% from the March 15th total of 126,800 shares. Approximately 21.6% of the company’s shares are short sold. Based on an average daily volume of 384,500 shares, the days-to-cover ratio is currently 1.9 days.
TRxADE HEALTH stock opened at $2.28 on Wednesday. The firm has a market capitalization of $18.65 million, a P/E ratio of -3.51 and a beta of 1.13. TRxADE HEALTH has a 1 year low of $1.64 and a 1 year high of $10.82. The business has a 50-day moving average of $2.03 and a 200-day moving average of $2.90.
TRxADE HEALTH (NASDAQ:MEDS – Get Rating) last posted its earnings results on Monday, March 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.05. TRxADE HEALTH had a negative return on equity of 50.16% and a negative net margin of 53.76%. On average, equities research analysts expect that TRxADE HEALTH will post -0.32 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC acquired a new position in shares of TRxADE HEALTH in the 3rd quarter valued at approximately $71,000. Virtu Financial LLC acquired a new position in shares of TRxADE HEALTH in the 4th quarter valued at approximately $41,000. Susquehanna International Group LLP acquired a new position in shares of TRxADE HEALTH in the 4th quarter valued at approximately $50,000. Renaissance Technologies LLC acquired a new position in shares of TRxADE HEALTH in the 4th quarter valued at approximately $51,000. Finally, Citadel Advisors LLC acquired a new position in shares of TRxADE HEALTH in the 4th quarter valued at approximately $60,000. Institutional investors and hedge funds own 6.82% of the company’s stock.
TRxADE HEALTH Company Profile (Get Rating)
TRxADE HEALTH, Inc operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name.
- Get a free copy of the StockNews.com research report on TRxADE HEALTH (MEDS)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for TRxADE HEALTH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRxADE HEALTH and related companies with MarketBeat.com's FREE daily email newsletter.